DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Add-on Effects of Tiotropium Over Formoterol in Exercise Tolerance on Chronic Obstructive Pulmonary Disease Patients

Information source: Federal University of São Paulo
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Pulmonary Disease, Chronic Obstructive; Chronic Bronchitis; Pulmonary Emphysema

Intervention: Formoterol plus Placebo (Tiotropium) (Drug); Formoterol plus Tiotropium (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Federal University of São Paulo

Official(s) and/or principal investigator(s):
J Alberto Neder, MD, phD, Principal Investigator, Affiliation: Federal University of Sao Paulo

Summary

The primary objective is to comparatively evaluate the isolated effects of a long-acting beta2-adrenergic (formoterol fumarate 12µg b. i.d. via Aeroliser) and combined with a long-acting anti-cholinergic (tiotropium bromide 18µg o. d via Handihaler) on breathlessness, dynamic hyperinflation and exercise tolerance in patients with advanced, but stable, chronic obstructive pulmonary disease. The study hypothesis is that combining long acting bronchodilators with different action mechanisms would promote synergistic effects on clinical outcomes.

Clinical Details

Official title: Randomised Cross-over Study to Compare the Effect of Formoterol Plus Tiotropium Versus Formoterol Monotherapy on Breathlessness, Dynamic Hyperinflation and Exercise Tolerance in Moderate-to-severe Stable COPD Patients

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Percentage Change in Exercise Tolerance From Baseline at 2 Weeks

Secondary outcome: Mean Score on the Transitional Dyspnea Index (TDI)

Detailed description: This will be a single center, randomized, double-blind study consisting of two 2-week treatment periods separated by a 5-7 days washout phase without long-acting bronchodilators. Eligible patients who complete the one week screening phase will be randomized to one of two

treatment sequences: 1) Formoterol - -> Formoterol + Tiotropium or 2) Formoterol + Tiotropium

- -> Formoterol. During the treatment periods, patients will be allowed to use a short-acting

beta2-adrenergic+short-acting anticholinergic as rescue medication (salbutamol+ipratropium via MDI)

Eligibility

Minimum age: 40 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- COPD patients aged ≥ 40 years with stable moderate-to-severe airflow obstruction

(FEV1 < 70% and FEV1/FVC ≤ 70% of predicted normal value) post-bronchodilator

- presenting with a long history of smoking (> 20 pack-years) and chronic

breathlessness (Baseline Dyspnoea Index total score < 9) Exclusion Criteria:

- significant cardiovascular disease, hospitalization for COPD exacerbation or presence

of a respiratory tract infection within 1 month of screening

- current or childhood asthma

- a history of allergic rhinitis or other atopic disease

- inability to interrupt usual bronchodilator medication

- use of oral steroids within a month before screening

- need for long-term oxygen therapy, arterial oxygen saturation < 85% at rest anemia,

hypo- and hyperthyroidism, hyperadrenergic state

- uncontrolled insulin dependent diabetes mellitus, malignancy, or any disease or

condition which limits exercise performance other than COPD

- change in inhaled corticosteroid or theophylline use within 1 month prior to

screening

Locations and Contacts

Pulmonary Function and Clinical Exercise Physiology Unit (SEFICE), Sao Paulo 04020-050, Brazil
Additional Information

Starting date: November 2007
Last updated: January 12, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017